Lasmiditan for the Acute Treatment of Migraine


(December 17, 2024)

Methods

These bulletins are not systematic reviews and do not involve critical appraisal or include a detailed summary of study findings. Rather, they present an overview of the technology and available evidence. They are not intended to provide recommendations for or against a technology.

Literature Search Strategy

A limited literature search was conducted by an information specialist on key resources including MEDLINE All (1946–) via Ovid, Embase (1974–) via Ovid, PubMed, the Cochrane Library, the University of York Centre for Reviews and Dissemination databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concept was lasmiditan. The initial search was conducted on September 27, 2019. Regular alerts updated the search until project completion; only citations retrieved before February 3, 2020, were incorporated into the analysis. No filters were applied to limit the retrieval by study type. Retrieval was not limited by publication date or by language. Where possible, retrieval was limited to the human population.

Study Selection

One author screened the literature search results and reviewed the full text of all potentially relevant studies. Studies were considered for inclusion if the intervention was lasmiditan for the acute treatment of migraine. Conference abstracts and grey literature were included when they provided additional information to that available in the published studies.

Peer Review

A draft version of this bulletin was reviewed by one clinical expert. The manufacturer was also given the opportunity to comment on an earlier draft.